Enzymit, a synbio company pioneering cell-free biomanufacturing, has partnered with Cosun, a leader in sustainable plant-based ingredients, to successfully produce hyaluronic acid (HA) at a 200-liter pilot scale. Using an enzyme-only, cell-free process, they generated multi-kilogram quantities of high-purity HA, demonstrating greater efficiency and consistency than traditional fermentation methods.
Hyaluronic acid is a highly valuable biopolymer used in dermal fillers, wound healing, drug delivery, and tissue engineering. With the global market projected to reach nearly $16 billion by 2035, the demand for high-quality biomaterials is rapidly growing.
Enzymit’s innovative process is the first to enable manufacturers to control HA’s size during production. Using standardized enzymatic steps, they can produce HA ranging from about 10 kDa to 4 MDa with narrow size distribution, simply by adjusting process parameters—no need to change enzymes or organisms.
Marie Dobenesque, CTO of Cosun RD&I, said, “We’re proud to support Enzymit’s journey from lab to pilot scale. Their process development and factory operation were successful using existing assets, showing this cell-free technology is becoming an industrial reality in record time.”
This platform leverages AI-designed enzymes to synthesize complex bioproducts faster, cleaner, and more efficiently—without living cells. Gideon Lapidoth, CEO of Enzymit, emphasizes that this breakthrough not only advances HA production but also signals a future where molecular biomanufacturing is driven by precision, removing biological bottlenecks.
